TICKERNERD
Menu
PREPREConsumer Defensive · Packaged Foods

PRE Stock Forecast: Prenetics Global Ltd. Price Predictions for 2026-2027

Last close, 4 Nov 2026
$16
−0.56% on the day

The 7 Wall Street analysts covering Prenetics Global Ltd. hold a median 12-month price target of $37 — +129.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 35 of 100 as at 4 Nov 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$321.4M
Ticker Nerd rank
35/ 100
Median analyst target
$37
Analysts covering
7
Revenue$46.5M+162.9% y/y
Operating income−$21.9M
Net income−$9.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−13.1%
1M
−20.2%
YTD
+2.2%
1Y
+25.7%
From 52W high
−38.7%
From 52W low
+36.6%
$12
$26
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

PRE stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Prenetics Global Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 4 Nov 2026
35/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
75
Size
62
Growth
54
Accruals
52
Issuance
49
Revisions
49
Quality
21
Volatility
21
Value
13

Momentum (75): The shares have been drifting up relative to others.

Value (13): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

PRE stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PRE, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$20$30$40$50$60Jan 26Apr 26Jul 26Oct 26PREHigh $54Median $37Low $30

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says7 analysts
7 Buy0 Hold0 Sell
Low $30Median $37High $54

The green dot is the last close — the median target sits +129.8% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 2 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
26 Oct 2026Maxim GroupInitiatesBuy$41
12 Oct 2026Lucid Capital MarketsInitiatesBuy$54
12 Oct 2026Lucid Capital MarketsInitiatesBuy—
17 Sept 2026Craig-HallumInitiatesBuy—
17 Sept 2026Craig-HallumInitiatesBuy$40
27 Aug 2026B. Riley SecuritiesInitiatesBuy$37
27 Aug 2026B. Riley SecuritiesInitiatesBuy—
15 July 2026BenchmarkMaintainsBuy$30 → $40
15 July 2026BenchmarkMaintainsBuy—
16 June 2026BenchmarkInitiatesBuy—
16 Mar 2026Lake StreetInitiatesBuy—
29 Oct 2025Cantor FitzgeraldMaintainsOverweight—
16 Jan 2025Cantor FitzgeraldReiteratesOverweight—
4 Dec 2024Cantor FitzgeraldReiteratesOverweight—
4 Apr 2024Cantor FitzgeraldMaintainsOverweight—
26 Sept 2023Cantor FitzgeraldReiteratesOverweight$4.00
19 Sept 2023Cantor FitzgeraldMaintainsOverweight$6.00 → $4.00
22 Aug 2023Cantor FitzgeraldReiteratesOverweight—
18 Jan 2023Cantor FitzgeraldInitiatesOverweight$7.00
28 July 2015BarclaysMaintainsOverweight$137 → $140

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

PRE appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

PRE vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 4 Nov 2026, Prenetics Global Ltd. returned +25.7% against +14.8% for the S&P 500, dividends included.

PRE vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160180200220Jan 26Apr 26Jul 26Oct 26PRES&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

PRE analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Prenetics Global Ltd. (PRE) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
1.1×

Cheaper than 70% of US stocks

Price / sales
2.1×

Cheaper than 50% of US stocks

Price / book
3.1×

Cheaper than 30% of US stocks

EV / EBITDA
−2.9×

Cheaper than 77% of US stocks

Growth & margins
Revenue growth (YoY)
210.7%

Higher than 96% of US stocks

Earnings growth (YoY)
162.9%

Higher than 89% of US stocks

Gross margin
65.0%

Higher than 78% of US stocks

Operating margin
−45.1%

Higher than 17% of US stocks

Net margin
−30.4%

Higher than 13% of US stocks

Returns & dividend
Return on equity
−47.0%

Higher than 22% of US stocks

Return on assets
−18.9%

Higher than 20% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Prenetics Global Ltd. (PRE) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Prenetics Global Ltd. has a market value of $321.4M and an enterprise value of $156.4M.

  • Revenue in the twelve months to 30 June 2026: $142.6M. The latest quarter grew 210.7% year on year.

  • Net income over the same four quarters: −$48.3M, a −33.9% net margin.

  • Shares outstanding: 15.1M.

  • Trailing P/E: 1.1×; forward P/E: −7.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Prenetics Global Ltd. employs 98 people — $1.5M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 3 Nov 2026

Data provided by Twelve Data

Peers

PRE vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelPackaged Foods
CompanyMarket capTKN rank
PREPrenetics Global Ltd.$321.4M35
ENHAEnhanced Group, Inc.$281.3M6
USNAUSANA Health Sciences, Inc.$262.0M85
BRCCBRC, Inc.$244.0M58
NATRNature's Sunshine Products, Inc.$225.9M81
LWAYLifeway Foods, Inc.$337.8M46
BGSB&G Foods, Inc.$208.9M53

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Prenetics Global Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest PRE news & analysis

Prenetics' IM8 Names Brian J. Rosin as Successor Chief Financial Officer

GlobeNewsWire · 3 Nov 2026neutral

Prenetics’ IM8 named Brian J. Rosin as successor chief financial officer, completing a planned leadership transition. Prenetics said its finance leadership function is now based in the United States and that it will report third-quarter 2026 results on November 18, followed by a live-streamed earnings event and Q&A.

Why it matters — The appointment and relocation are relevant to PRE watchers because the excerpt says Prenetics’ revenue is almost entirely from IM8.

Prenetics' IM8 CEO and CFO Purchase $1.0 Million of Shares in the Open Market Following Second Quarter Results

GlobeNewsWire · 26 Aug 2026positive

Prenetics Global Limited announced that CEO Danny Yeung and CFO Brian Rosin purchased $1.0 million of the company's ordinary shares on the open market between August 20 and August 25, 2026, following the release of its second quarter 2026 financial results. Their cumulative personal investment since November 2025 has reached approximately $3.75 million.

Why it matters — Buying activity by senior executives on the open market can signal management confidence in the company's direction and financial outlook.

Prenetics Global: Marketing Mastery The Key To Robust Revenue Growth

Seeking Alpha · 24 Aug 2026positive

Prenetics Global has grown to 140,000 subscriptions in 20 months, driven by its IM8 supplement and AI-powered marketing. The company credits its marketing mastery—using A/B and multivariate testing to refine advertising messages—and a deal with General Catalyst that allows it to finance up to 70% of customer acquisition costs without equity dilution or debt.

Why it matters — A PRE watcher would care because the company's rapid subscription growth and financing arrangement for customer acquisition costs highlight its marketing strategy without relying on equity dilution or debt.

Prenetics Global Limited (PRE) Q2 2026 Earnings Call Transcript

Seeking Alpha · 22 Aug 2026neutral

Prenetics Global Limited (PRE) held its Q2 2026 earnings call, and a transcript of the call was published on Seeking Alpha.

Why it matters — The earnings call transcript provides PRE watchers with insight into the company's latest quarterly results and management commentary.

Prenetics' IM8 Announces Two-Time Golden Globe-Nominated Actress and Producer Lily Collins as IM8 Global Ambassador and Shareholder in Multi-Year Partnership

GlobeNewsWire · 20 Aug 2026positive

Prenetics' IM8 announced a multi-year global partnership with actress and producer Lily Collins, who becomes IM8's first Global Ambassador from film and television and a shareholder in Prenetics. The announcement coincided with Prenetics raising its FY 2026 revenue guidance to $220+ million and initiating FY 2027 guidance of $400+ million.

Why it matters — PRE watchers would care because the partnership expands IM8's brand reach into global entertainment and culture while the company simultaneously raised its revenue guidance.

FAQ

Frequently asked questions about PRE stock

What is the PRE stock price forecast for 2026-2027?

The 7 Wall Street analysts covering Prenetics Global Ltd. have a median 12-month price target of $37, with estimates ranging from $30 to $54. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is PRE stock a buy right now?

Of the 7 analysts covering Prenetics Global Ltd., 7 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Prenetics Global Ltd. 35 out of 100 across roughly 4,600 US stocks as at 4 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PRE?

As at 4 Nov 2026, Prenetics Global Ltd. ranks 35 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (75 of 100).

Will PRE stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies +129.8% from the last close, and Ticker Nerd's factor model ranks Prenetics Global Ltd. 35 out of 100 as at 4 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the PRE stock forecast for 2030?

No analyst covering Prenetics Global Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PRE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $30 to $54 over the next 12 months.

How has PRE stock performed over the past year?

Prenetics Global Ltd. returned +25.7% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Prenetics Global Ltd. do?

Prenetics Global Limited Class A Ordinary Share is the common equity security of Prenetics Global Limited, a health sciences company focused on consumer health products and services. The company operates through brands and platforms that include IM8, which offers scientifically formulated supplements and longevity-focused nutrition products, Europa, which provides sports nutrition products, and CircleDNA, a direct-to-consumer DNA testing service.

What is the latest news on PRE?

The most recent item we track (GlobeNewsWire, 3 Nov 2026): "Prenetics' IM8 Names Brian J. Rosin as Successor Chief Financial Officer". Prenetics’ IM8 named Brian J. Rosin as successor chief financial officer, completing a planned leadership transition. Prenetics said its finance leadership function is now based in the United States and that it will report third-quarter 2026 results on November 18, followed by a live-streamed earnings event and Q&A.

Company

About Prenetics Global Ltd.

Prenetics Global Limited Class A Ordinary Share is the common equity security of Prenetics Global Limited, a health sciences company focused on consumer health products and services. The company operates through brands and platforms that include IM8, which offers scientifically formulated supplements and longevity-focused nutrition products, Europa, which provides sports nutrition products, and CircleDNA, a direct-to-consumer DNA testing service. Prenetics Global Limited serves consumers seeking wellness, nutrition, and genetic insights, with its products distributed across multiple markets in the United States, Hong Kong, and other international regions. The Class A Ordinary Share represents an ownership interest in the company’s current health and wellness business segments and reflects its role in the broader consumer health sciences market.

CEO Mr. Sheng Wu Yeung · 98 employees · Hong Kong · https://www.prenetics.com